Much of the ongoing morbidity in patients suffering majordepressive disorders is related to current treatments failing to produce complete remission. Many patients can be considered to have treatment-resistant depression (TRD), with failure to fully remit with adequate doses and durations of 2 or more antidepressant trials [1, 2] . TRD is associated with greater disability, mortality, morbidity, somatic symptoms, risk of relapse and societal cost [3, 4] . We report on a pilot study of mindfulness-based cognitive therapy (MBCT) for TRD.